Teva Still A 'Must-Own' Stock, Worth $86

By: via Benzinga
In a report published Tuesday, Citi analyst Liav Abraham maintained a Buy rating on Teva Pharmaceutical Industries Ltd (ADR) (NYSE: ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.